Peptide therapeutics against viral infections

  • Novel patented platform technology

  • Targeting all enveloped viruses

  • Insensitive to mutations and seasonal variation

  • Mitigating future pandemics

Virenc AB is a startup company established in 2024 to develop and commercialise antiviral research conducted at Örebro University. Örebro University Holding AB is a founding partner together with the research group led by Hazem Khalaf and Torbjörn Bengtsson.

WHAT WE DO IS IMPORTANT

The emergence of viral infectious diseases with epidemic and pandemic potential has dramatically increased during recent decades with escalating threats to human health and the society. Contributing factors to this worrying development are among other things growing human population with expanded cities, increased travels and climate change.

New technologies and platforms for pharmaceutical interventions including novel antiviral drugs are urgently needed for prevention and treatment of viral infections and to counteract the transmission of the pathogens between humans leading to higher risks for outbreaks, epidemics and pandemics.

Co-founders Torbjörn Bengtsson and Hazem Khalaf